|
YM598 in patients with rising PSA after initial therapy for localized prostate cancer Clinical Trials Data presented on Clinical Trials Search is not meant to be a substitute for qualified health advice, visits or treatment with a real mD. We are not doctors. Always consult your doctor about YM598 in patients with rising PSA after initial therapy for localized prostate cancer conditions. Clinical Trials Search.org is a site devoted to listing clinical research studies in human subjects. YM598 in patients with rising PSA after initial therapy for localized prostate cancer Clinical research trials and YM598 in patients with rising PSA after initial therapy for localized prostate cancer healthcare trials happen in many of places across the United States. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally assess the effectivity of new drugs. The purpose of the studies / projects is to solve particular human medical questions. Clinical trials are a popular way for doctors, government agencies, and private sector companies to discover cures for all varieties of conditions, such as YM598 in patients with rising PSA after initial therapy for localized prostate cancer. YM598 in patients with rising PSA after initial therapy for localized prostate cancer Clinical Trials and other clinical trials allow volunteers to have health treatment alternatives before they are available to the masses. Some times the human subjects obtain treatment for without cost, and sometimes they are compensated for their time. Occasionally there is a cost for a YM598 in patients with rising PSA after initial therapy for localized prostate cancer clinical trial. Test subjects oftentimes receive the most effective healthcare possible for their YM598 in patients with rising PSA after initial therapy for localized prostate cancer condition. Dangers are a reality, however, and may include extra or frequent physician visits, healthcare dangers (possibly life-jeopardising), and/or the treatment being uneffective. Trials are federally governed with rigorous guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "Y" Clinical Trials Conditions > YM598 in patients with rising PSA after initial therapy for localized prostate cancer  YM598 in patients with rising PSA after initial therapy for localized prostate cancer
YM598 in patients with rising PSA after initial therapy for localized prostate cancer
For Condition: Prostate Cancer
Status: Terminated
Sponsor(s): Yamanouchi Pharma America ,
Synopsis: The purpose of this study is to determine the optimal dosage of YM598 for slowing down disease progression in patients with rising PSA after initial therapy for localized prostate cancer
Details:
Eligibility:
Study Type: Interventional, Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety/Efficacy Study
Minimum Age/Maximum Age: 18 Years/
Genders: Male
Protocol Entry Criteria:
Total Enrollment:
Location and Contact Information:
Hospital Universitario Principe de Asturias, Servicio de UrologĂa, Ctra.
Madrid, ,
Spain
Bielanski Hospital, Department of Urology
Warszawa, ,
Poland
Medical University, Clinic of Urology
Wroclaw, ,
Poland
Krummbogen 15
Marburg, ,
Germany
Klinik und Poliklinik für Urologie, Universitätsklinikum Carl-Gustav-Carus
Dresden, ,
Germany
Department of Urology, Norfolk & Norwich Hospital
Norwich, ,
United Kingdom
Clinic of Urology, University Hospital
Prague, ,
Czech Republic
MedSource Poland
Gdansk, ,
Poland
Private Urology Out-patient Ward
Jablonec nad Nisou, ,
Czech Republic
Clinic of Urology, University Hospital
Olomouc, ,
Czech Republic
Haingasse 22
Bad Homburg, , 61348
Germany
University Clinic AZ
Brussels, ,
Belgium
Klinik u. Poliklinik für Urologie, Philipps Universität, Baldingerstraße
Marburg, ,
Germany
Department of Urology, Taunton & Somerset Hospital
Taunton, ,
United Kingdom
Department of Urology, Bristol Royal Infirmary
Bristol, ,
United Kingdom
Department of Urology, Gartnavel Hospital
Glasgow, ,
United Kingdom
Regional Hospital, Department of Urology
Bydgoszcz, ,
Poland
Complejo Hospitaliaro Juan Canalejo, Servicio de UrologĂa
Corunna, ,
Spain
Clinic of Urology, University Hospital
Králové, ,
Czech Republic
Oncology Center, Department of Urinary Tract Cancer
Warszawa, ,
Poland
Fundacion Hospital AlcorcĂłn, Servicio UrologĂa
Madrid, ,
Spain
HĂ´pital Bichat, service de Urology
Paris, ,
France
University Clinic UCL St. Luc
Brussels, ,
Belgium
Additional Information:
Study ID Numbers: 598-CL-004;
Study Start Date:
Record last reviewed: February 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00050297
Other Prostate Cancer Studies:
1. Study of Paclitaxel, Estramustine Phosphate and Thalidomide for Patients With Metastatic Androgen-Independent Prostate Carcinoma
2. Perifosine to Treat Prostate Cancer
3. Vaccine Therapy in Treating Patients With Gastric Cancer, Non-Small Cell Lung Cancer, Prostate, or Ovarian Cancer
4. ASCENT: Androgen Independent Prostate Cancer Study of Calcitriol Enhancing Taxotere
5. Phase I/II Study of IV Estramustine Combined with Taxol in Patients with Hormone Refractory Adenocarcinoma of the Prostate
Related Studies:
Other Prostate Cancer Clinical Trials
Other Clinical Trials
Other Glasgow Clinical Trials
YM598 in patients with rising PSA after initial therapy for localized prostate cancer
|
|
|
|
|
|
|
|
